Drug search by name

Antihemophilic Factor/von Willebrand Factor Complex (Human) (Wilate) and Thromboembolic events

Result of checking the interaction of drug Antihemophilic Factor/von Willebrand Factor Complex (Human) (Wilate) and disease Thromboembolic events for safety when used together.

Check result:

Antihemophilic Factor/von Willebrand Factor Complex (Human) (Wilate) <> Thromboembolic events

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Thromboembolic events have been reported in patients receiving antihemophilic factor/von Willebrand factor complex replacement therapy. Care should be exercised in the existence of known risk factors for thrombosis. Endogenous high levels of factor VIII have also been associated with thrombosis, but no causal relationship has been established. Caution is recommended and consider antithrombotic measures in all patients at risk who are receiving coagulation factor replacement therapy.

Antihemophilic Factor/von Willebrand Factor Complex (Human) (Wilate)

Generic Name: antihemophilic factor / von willebrand factor

Brand Name: Alphanate, Humate-P, Wilate, Wilstart, Dried Factor VIII Fraction Type 8Y, Haemate P, Optivate

Synonyms: Antihemophilic and von Willebrand factor complex, Antihemophilic Factor/von Willebrand Factor Complex (Human)

What is Antihemophilic Factor/von Willebrand Factor Complex (Human) (Wilate)?